PCR Technologies Market by Technology, Product, Application, End-user and Region - Global Forecast to 2025 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global PCR Technologies Market by Technology (Conventional, qPCR, dPCR), Product (Instrument, Reagents, Software), Application (Genotyping, Sequencing, Gene Expression, Diagnostics), End-user (Academia, Pharma-Biotech, Applied), and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global PCR technologies market is projected to reach USD 9.8 billion by 2025 from USD 7.2 billion in 2020, at a CAGR of 6.3% from 2020 to 2025.
The rising incidence of infectious diseases and genetic disorders across the world has spurred the demand for better and faster diagnostic tests. This has also boosted the overall pace of R&D in the PCR technologies market along with the availability of strong financial support in the form of investments, funds, and grants. These factors are driving the growth of PCR technologies market during the forecast period. However, high instrument costs - especially that of dPCR - and the technical limitations of PCR are expected to limit market growth to a certain extent.
The qPCR segment is expected to account for the largest market share of the global PCR technologies market in 2020
The qPCR segment is expected to account for the largest share among PCR techniques in 2020. The expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing private-public funding for life sciences research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples) are expected to drive the growth of the qPCR market.
Reagents and consumables segment to show the highest growth in the PCR technologies market during the forecast period
The reagents and consumables segment will show the highest growth in the PCR technologies market during the forecast period. The growth of this segment can be attributed to factors such as the expanding applications of dPCR, the increasing number of dPCR-based analytical procedures among institutional researchers (such as CROs and pharma-biotech companies), and the rising availability of novel dPCR reagents worldwide. Additionally, the expansion of the application base of the dPCR technology in genetic/molecular research, clinical diagnosis, and forensics is expected to result in the commercialization of novel dPCR reagents.
North America to account for the largest share of the global market in 2020
North America accounts for the largest share of the PCR technologies market owing to the high incidence of chronic and genetic diseases, rising geriatric population, growing adoption of PCR techniques in research & academia, and significant public-private funding in the field of genome analysis. Further, the strong presence of major pharmaceutical and biotechnology companies in the US and ongoing initiatives by the Canadian government to support life science, genomic, and clinical research are other few factors influencing the demand for PCR products in this region.
- Rising Incidence of Target Infectious Diseases and Genetic Disorders
- Continuous Advancements in PCR Technologies
- Increasing Investments, Funds, and Grants
- Increasing Use of Biomarker Profiling for Disease Diagnostics
- Successful Completion of the Human Genome Project
- High Device Costs Associated with dPCR
- Technical Limitations of qPCR and dPCR
- Growing Market Penetration in Emerging Countries
- Shift from Plant-Derived to Genome-Based Drug Discovery
- Adoption and Implementation of MIQE Guidelines
- Development of Compact, Portable, and Lab-On-Chip PCR Devices
- Ongoing Technological Integration with the PCR Process
- Abbott Laboratories
- Agilent Technologies, Inc.
- Analytik Jena AG (A Wholly Owned Subsidiary of Endress+Hauser AG)
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Biomerieux S.A.
- Danaher Corporation
- Eppendorf AG
- F. Hoffman-La Roche Ltd.
- Fluidigm Corporation
- Merck KGaA
- Promega Corporation
- Qiagen N.V.
- Takara Bio, Inc.
- Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/wlzqec
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900